Treatment of acute hepatitis C;Traitement de l'hépatite aigué C

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Grangé, Jean Didier ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BETA INTERFERON; HEPATITIS C VACCINE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ACUTE HEPATITIS; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; NEEDLESTICK INJURY; NEWBORN HEPATITIS; NEWBORN INFECTION; PREVALENCE; VIRUS INFECTION; VIRUS TRANSMISSION;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; CONTROLLED CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON ALFA-2B; INTERFERON-BETA; MALE; META-ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; RISK FACTORS; TIME FACTORS;

EID: 0036265831     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors
2. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection
3. Quelles sont les indications du traitement dans l'hépatite aiguë C
4. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
5. The natural history of community-acquired hepatitis C in the United States
6. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C
7. Hepatitis C: The clinical spectrum of disease
8. Treatment of acute hepatitis C with interferon-alpha 2b prevents chronicity
9. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
10. Natural beta interferon in acute type-C hepatitis patients: A randomized controlled trial
11. Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: Etiology and natural history
12. Role of the specific T-cell response for clearance and control of hepatitis C virus
13. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
14. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study
15. Hepatitis C virus viremia following clinical resolution of acute hepatitis C
16. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
17. Acute hepatitis C: Natural course and response to antiviral treatment
18. Recovery, persistence and sequelae in hepatitis C virus infection: A perspective on long-term outcome
19. Natural history of liver fibrosis progression in patients with chronic hepatitis C
20. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: Results of a randomized trial
21. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively controlled, multicenter study
22. EASL International Consensus Conference on hepatitis C: Paris, 26-28, February 1999, Consensus Statement
23. Resolution of acute hepatitis C after therapy with natural beta interferon
24. Interferon-alpha in acute post transfusion hepatitis C: A randomized, controlled trial
25. Report on therapy of interferon alpha 2b in patients with acute hepatitis C
26. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C
27. Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study
28. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C
29. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis
30. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha
31. Outcome of acute hepatitis C and role of interferon alpha therapy
32. High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for acute hepatitis C
33. Interferon therapy in haemodyalysis patients with acute hepatitis C virus infection and factors that predict response to treatment
34. Interferon therapy for acute hepatitis C: Changes in serum markers associated with HCV and clinical effects
35. High-dose interferon-alpha-2b treatment prevents chronicity in acute hepatitis C: A pilot study
36. A trial of interferon beta la (IFN b 1a) for 4 weeks for therapy of acute hepatitis C
37. Timing of IFN therapy initiation for acute hepatitis C after accidental needlestick
38. Treatment of acute hepatitis C with interferon alfa 2b
39. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
40. Interferon as treatment for acute hepatitis C. A meta-analysis
41. Interferon therapy for acute hepatitis C viral infection - A review by meta-analysis
42. Treatment of acute hepatitis C virus infection
43. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update
44. Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis
45. Acute hepatitis C
46. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level
47. Perspectives for a vaccine against hepatitis C virus
48. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
49. Hépatite virale C et grossesse
50. Mother-to-infant transmission of hepatitis C virus
51. Mother-to-child transmission of hepatitis C virus: Evidence for preventable peripartum transmission
52. Mother-to-child transmission of hepatitis C virus: A case-control study of risk factors